Norton L - Search Results

1

Microdissection and molecular genetic analysis of HER2/neu in breast carcinoma.

Youngson BJ, Anelli A, Van Zee KJ, Borgen PI, Norton L, Rosen PP. Youngson BJ, et al. Among authors: norton l. Am J Surg Pathol. 1995 Dec;19(12):1354-8. doi: 10.1097/00000478-199512000-00002. Am J Surg Pathol. 1995. PMID: 7503357

2

Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis.

Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. Rosen PP, et al. Among authors: norton l. Cancer. 1995 Mar 15;75(6):1320-6. doi: 10.1002/1097-0142(19950315)75:6<1320::aid-cncr2820750614>3.0.co;2-c. Cancer. 1995. PMID: 7882282

3

Immunohistochemical detection of cathepsin D in T2N0M0 breast carcinoma.

Armas OA, Gerald WL, Lesser ML, Arroyo CD, Norton L, Rosen PP. Armas OA, et al. Among authors: norton l. Am J Surg Pathol. 1994 Feb;18(2):158-66. doi: 10.1097/00000478-199402000-00005. Am J Surg Pathol. 1994. PMID: 8291654

4

Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up.

Rosen PP, Groshen S, Kinne DW, Norton L. Rosen PP, et al. Among authors: norton l. J Clin Oncol. 1993 Nov;11(11):2090-100. doi: 10.1200/JCO.1993.11.11.2090. J Clin Oncol. 1993. PMID: 8229123

5

Immunophenotype of intraductal carcinoma.

Bose S, Lesser ML, Norton L, Rosen PP. Bose S, et al. Among authors: norton l. Arch Pathol Lab Med. 1996 Jan;120(1):81-5. Arch Pathol Lab Med. 1996. PMID: 8554451

6

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Baselga J, et al. Among authors: norton l. J Clin Oncol. 1996 Mar;14(3):737-44. doi: 10.1200/JCO.1996.14.3.737. J Clin Oncol. 1996. PMID: 8622019 Clinical Trial.

7

BRCA-associated breast cancer: absence of a characteristic immunophenotype.

Robson M, Rajan P, Rosen PP, Gilewski T, Hirschaut Y, Pressman P, Haas B, Norton L, Offit K. Robson M, et al. Among authors: norton l. Cancer Res. 1998 May 1;58(9):1839-42. Cancer Res. 1998. PMID: 9581822

8

BRCA-associated breast cancer in young women.

Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, Hirschaut Y, Pressman P, Rosen PP, Lesser ML, Norton L, Offit K. Robson M, et al. Among authors: norton l. J Clin Oncol. 1998 May;16(5):1642-9. doi: 10.1200/JCO.1998.16.5.1642. J Clin Oncol. 1998. PMID: 9586873

9

Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.

Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Baselga J, et al. Among authors: norton l. Semin Oncol. 1999 Aug;26(4 Suppl 12):78-83. Semin Oncol. 1999. PMID: 10482197 Clinical Trial.

10

Refining the origins of breast cancer.

Norton L, Rosen PP, Rosen N. Norton L, et al. Nat Med. 1995 Dec;1(12):1250-1. doi: 10.1038/nm1295-1250. Nat Med. 1995. PMID: 7489402 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,020 results

Search Page

Filters